Edoxaban
Cardiovascular - AF
Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer
Patell R, Hsu C, Shi M et al.
Haematologica. 2024;109(6):1849-1856.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer: A plain language summary of the DESTINY-Breast03 study
Cortés J
Future Oncol. 2023. doi: 10.2217/fon-2023-0422. Online ahead of print.
T-DXd
Breast Cancer
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
Kapil A, Spitzmüller A, Brieu N, et al.
Sci Rep. 2024;14(1):12129
Other/Multi
Lung Cancer
Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: A review
Kurzrock R, Chaudhuri AA, Feller-Kopman D, et al.
Cancer Metastasis Rev. 2024. doi: 10.1007/s10555-024-10187-6. Epub ahead of print.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
Shitara K, Bang Y-J, Iwasa S, et al.
Nat Med. 2024. doi: 10.1038/s41591-024-02992-x. Epub ahead of print.
Quizartinib
Hematology
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN
Montalban-Bravo G, Jabbour E, Chien K, et al.
Leuk Res. 2024;142:107518.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France
Petit T, Hajjaji N, Antoine E-C, et al.
Cancer Med. 2024;13(9):e7168.
T-DXd
Tumor-agnostic
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): An international, phase 2 study
Li B, Meric-Bernstam F, Bardia A, et al.
Lancet Oncol. 2024;25(6):707-719.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): Patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Fehm T, Cottone F, Dunton K, et al.
Lancet Oncol. 2024;25(5):614-625.
Edoxaban
Cardiovascular - AF
Cardiovascular - VTE
Periprocedural edoxaban management and clinical outcomes in patients undergoing transcatheter cardiovascular procedures in the EMIT-AF/VTE program
Unverdorben M, Colonna P, Jin J, et al.
Clin Appl Thromb Hemost. 2024;30:10760296241260728. doi: 10.1177/10760296241260728.